Axsome Therapeutics, Inc. (AXSM) Covered Calls
You can sell covered calls on Axsome Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AXSM (prices last updated Fri 4:16 PM ET):
| Axsome Therapeutics, Inc. (AXSM) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 86.70 | -1.27 | 85.56 | 90.55 | 589K | - | 4.3 |
| Covered Calls For Axsome Therapeutics, Inc. (AXSM) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jan 17 | 87.5 | 9.90 | 80.65 | 8.5% | 141% | |
| Feb 21 | 87.5 | 10.60 | 79.95 | 9.4% | 60.2% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
| Top 10 Open Interest For Jan 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | XLF covered calls | 1. | NMRA covered calls | |
| 2. | SLV covered calls | 7. | SPY covered calls | 2. | QBTS covered calls | |
| 3. | AAPL covered calls | 8. | IWM covered calls | 3. | QUBT covered calls | |
| 4. | EEM covered calls | 9. | TSLA covered calls | 4. | QS covered calls | |
| 5. | INTC covered calls | 10. | TLT covered calls | 5. | JSPR covered calls | |
Want more examples? AXS Covered Calls | AXTA Covered Calls
